DURHAM – Velocity Clinical Research disclosed early Wednesday the first in a “series of deals” that will expand the fast-growing life science services firm into Europe.
Velocity says it has acquired Clinical Research Hamburg to establish a footprint overseas.
It’s “the first in a series of deals lined up across the [United Kingdom] and Germany,” the company points out.
Financial terms weren’t disclosed.
Says Paul Evans, Chief Executive Officer Velocity: “This is just the beginning. Velocity has ambitious plans to establish itself as a global player, making more clinical research succeed. The focus now is on site integration rather than affiliation, allowing for greater predictability and more efficient data collection and delivery.”
Founded in 2017, the company was sold by NaviMed to private equity firm, GHO Capital a year ago and rapid growth has continued.
The company now has 32 sites. It expanded into India in February.
Durham’s Velocity Clinical Research buys India-based company, adds new CTO
